Posted by Michael Wonder on 24 Jan 2017
European Commission initiative improves information for patients on biosimilar medicines
23 January 2017 - For the third year in a row, the European Commission will organise a multi-stakeholder workshop on biosimilar medicines (5 May 2017).
Today, the European Commission published a unique Q&A for patients with reliable information on biosimilar medicines. Stakeholders value these efforts to provide unbiased, scientifically correct and yet easy to understand information on biosimilar medicines through the Q&A on Biosimilar Medicines, now available in 7 EU languages.
This consensus information on biosimilar medicinal products was drafted for patients together with the European Medicines Agency, the European Commission and relevant stakeholders: the European Patients Forum, the European Federation of Crohn’s & Ulcerative Colitis Associations, the Standing Committee of European Doctors, European Federation of Pharmaceutical Industries and Associations, European Association for Bio-industries (EuropaBio) and Medicines for Europe.
